Therapeutic drug monitoring-Does it really matter?
Br J Clin Pharmacol
.
2024 Dec 30.
doi: 10.1111/bcp.16387.
Online ahead of print.
Authors
Hans Lennernäs
1
,
Jack Cook
2
,
Dennis A Hesselink
3
Affiliations
1
Department of Pharmaceutical Bioscience, Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
2
A2-Ai LLC, Ann Arbor, Michigan, USA.
3
Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
PMID:
39739997
DOI:
10.1111/bcp.16387
No abstract available
Publication types
Editorial
Grants and funding
211634Pj01H/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
243519Pj01H/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
HL is funded through grants obtained from the Swed/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
2020-02367/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
2024-03166/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)